1. Clinical & Scientific Overview
Human Insulin (Regular Soluble, Isophane NPH, & Premixed 30/70) (TIP-MED-000057, Reference Code [4.13]) is classified under
Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04) as a Recombinant Human Peptide Hormone; Short-Acting (Regular), Intermediate-Acting (NPH), and Biphasic Premixed (30% Regular + 70% NPH).
Within the Indian regulatory and compendial framework, it is governed under Schedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this preparation except under medical supervision' — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 04 [4.13], p. 51): Regular (Short-Acting): Actrapid (Novo Nordisk), Huminsulin R (Eli Lilly), Insugen-R (Biocon), Wosulin-R (Wockhardt). NPH (Intermediate-Acting): Insulatard (Novo), Huminsulin N (Lilly), Insugen-N. Premixed 30/70 (Biphasic): Mixtard 30/70 (Novo), Huminsulin 30/70 (Lilly), Insugen 30/70 (Biocon), Lupisulin-M 30/70 (Lupin) — Strengths & Dosage Forms: Vials (10 mL): 40 IU/mL (U-40) and 100 IU/mL (U-100); Prefilled Pens & Penfill/Cartridges (3 mL): Strictly 100 IU/mL (U-100)
Vials (10 mL): 40 IU/mL (U-40) and 100 IU/mL (U-100); Prefilled Pens & Penfill/Cartridges (3 mL): Strictly 100 IU/mL (U-100)
3. Mechanism of Action & Pharmacodynamics
Recombinant Human Peptide Hormone; Short-Acting (Regular), Intermediate-Acting (NPH), and Biphasic Premixed (30% Regular + 70% NPH) acting on target receptor/enzyme pathways in Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04): clinical efficacy is mediated via Recombinant Human Peptide Hormone; Short-Acting (Regular), Intermediate-Acting (NPH), and Biphasic Premixed (30% Regular + 70% NPH) for Type 1 diabetes mellitus; Type 2 diabetes mellitus inadequately controlled on oral agents, during pregnancy (GDM), acute hospitalisation/surgery, sepsis, steroid therapy, or advanced renal/hepatic failure (eGFR <30 mL/min)..
4. Therapeutic Indications & Evidence-Supported Uses
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus inadequately controlled on oral agents, during pregnancy (GDM), acute hospitalisation/surgery, sepsis, steroid therapy, or advanced renal/hepatic failure (eGFR <30 mL/min)
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Strictly individualised per blood glucose profile! Premixed Human Insulin 30/70 is typically administered subcutaneously twice daily (e.g., 2/3 of total daily dose before breakfast and 1/3 before dinner). Pharmacokinetic Profile: • Regular (Clear): Onset 30–45 min, Peak 2–4 h, Duration 6–8 h. • NPH (Cloudy): Onset 1.5–2 h, Peak 4–10 h, Duration 12–18 h. • Mixtard 30/70 (Cloudy): Onset 30 min, Peak 2–8 h, Duration up to 18–24 h.
Administration & Meal Timing: CRITICAL 30-MINUTE RULE: Human Regular and Premixed 30/70 insulins MUST be injected 30 minutes BEFORE starting breakfast or dinner! (Injecting right at the table causes early post-meal hyperglycaemia followed by late hypoglycaemia 3–4 hours later; injecting and then delaying food >45 minutes causes acute hypoglycaemia). | Premixed 30/70: Twice daily (30 min before breakfast and 30 min before dinner). NPH: Once daily at bedtime or twice daily.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Strictly renal-function dependent! The kidneys clear ~30–40% of exogenous circulating insulin. As eGFR drops below 45 mL/min and <30 mL/min, insulin half-life prolongs markedly ('renal honeymoon phenomenon')—total daily insulin dose typically must be reduced by 25–50% to prevent severe hypoglycaemia. Hepatic: Reduced hepatic glycogen stores in cirrhosis increase fasting hypoglycaemia risk.
Renal: Strictly renal-function dependent! The kidneys clear ~30–40% of exogenous circulating insulin. As eGFR drops below 45 mL/min and <30 mL/min, insulin half-life prolongs markedly ('renal honeymoon phenomenon')—total daily insulin dose typically must be reduced by 25–50% to prevent severe hypoglycaemia. Hepatic: Reduced hepatic glycogen stores in cirrhosis increase fasting hypoglycaemia risk.
Renal: Strictly renal-function dependent! The kidneys clear ~30–40% of exogenous circulating insulin. As eGFR drops below 45 mL/min and <30 mL/min, insulin half-life prolongs markedly ('renal honeymoon phenomenon')—total daily insulin dose typically must be reduced by 25–50% to prevent severe hypoglycaemia. Hepatic: Reduced hepatic glycogen stores in cirrhosis increase fasting hypoglycaemia risk.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated during episodes of hypoglycaemia. Only Regular (Clear) insulin may be given IV in hospital emergencies; NPH and Premixed 30/70 (Cloudy) must NEVER be injected IV!
Key Clinical Precautions: Renal: Strictly renal-function dependent! The kidneys clear ~30–40% of exogenous circulating insulin. As eGFR drops below 45 mL/min and <30 mL/min, insulin half-life prolongs markedly ('renal honeymoon phenomenon')—total daily insulin dose typically must be reduced by 25–50% to prevent severe hypoglycaemia. Hepatic: Reduced hepatic glycogen stores in cirrhosis increase fasting hypoglycaemia risk.
8. Adverse Effects Profile
- Hypoglycaemia (especially mid-morning or nocturnal with NPH/30-70 peak), weight gain (2–4 kg), lipohypertrophy (rubbery subcutaneous fat lumps at unrotated injection sites causing erratic, delayed insulin absorption), mild injection-site oedema.
- Severe neuroglycopenic hypoglycaemia (seizures, coma), hypokalaemia (with high-dose IV infusion), severe generalised insulin allergy (rare).
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Oral secretagogues, ACE inhibitors, beta-blockers (mask tachycardia/tremor and delay counter-regulatory glycogenolysis), fluoroquinolones, and alcohol potentiate hypoglycaemia
- Corticosteroids (prednisolone), thiazides, thyroid hormones, and sympathomimetics increase insulin requirements
- Pioglitazone + Insulin increases heart failure/oedema risk
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: CRITICAL SYRINGE-VIAL MATCH RULE: Indian CGHS/retail vials exist in TWO concentrations — 40 IU/mL (Red cap/label -> MUST use Red-cap 40 IU syringe ONLY) and 100 IU/mL (Yellow/Orange cap or cartridge -> MUST use Orange-cap 100 IU syringe or Pen ONLY). A 2.5-fold fatal overdose occurs if 100 IU/mL insulin is drawn into a 40 IU syringe. Roll NPH/Premix (Mixtard 30/70) gently 20 times between palms until uniformly milky (never shake); inject 30 min BEFORE meal. Store unopened vials at 2–8°C (never freeze); in-use vial/pen kept at room temperature (<25–30°C) away from sunlight, discard after 28 days.
- Meal & Clock Timing Instruction: CRITICAL 30-MINUTE RULE: Human Regular and Premixed 30/70 insulins MUST be injected 30 minutes BEFORE starting breakfast or dinner! (Injecting right at the table causes early post-meal hyperglycaemia followed by late hypoglycaemia 3–4 hours later; injecting and then delaying food >45 minutes causes acute hypoglycaemia). (Premixed 30/70: Twice daily (30 min before breakfast and 30 min before dinner). NPH: Once daily at bedtime or twice daily.)
- Missed Dose Protocol: If forgotten before the meal and remembered immediately after eating, contact the physician or follow the written sliding-scale adjustment (often a slightly reduced dose or monitoring). Never double the next scheduled insulin dose.
- Geriatric Dispensing Pearl: Frail elderly patients with poor vision, arthritis, or cognitive decline frequently misread syringe markings or forget to eat 30 minutes after injecting Mixtard 30/70. Prefer prefilled insulin pens (with audible click dials) and involve a family caregiver.
Storage, Stability & Dispensing Safeguards: COLD CHAIN MANDATORY (2°C–8°C): Store in a pharmaceutical refrigerator between 2°C and 8°C; DO NOT FREEZE. Protect from light and heat during dispensing.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 04 [4.13] (p. 51)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.